ISBER is excited to announce its keynotes speakers for the 2020 Annual Meeting & Exhibits: Drs. Dean Ornish (Preventive Medicine Research Institute, USA) and Nicolas Forraz (CTIBiotech, France)!
In April 2020, global leaders and disruptors from the broad spectrum of scientific community will converge at ISBER 2020 to address the impact of biobanks on science and how the related discoveries are establishing a roadmap to extend our knowledge network. From engaging with vulnerable populations to advances in artificial intelligence, experts at ISBER 2020 will highlight critical advances in biobanking and, for the first time, host a town hall to discuss trust in biospecimen banking and research with research participants, advocates, and other stakeholders.
The preliminary program for the meeting is now available at http://meetings.isber.org/2020/
ISBER is excited to announce the keynote speakers:
“The Transformative Power of Lifestyle Medicine”
Dean Ornish, MD, Preventive Medicine Research Institute
Dean Ornish is the founder and president of the nonprofit Preventive Medicine Research Institute, clinical professor of medicine at the University of California, San Francisco, and the author of six books, all national bestsellers. He has received numerous honors, including the Outstanding Young Alumnus Award from the University of Texas, Austin, and the National Public Health Hero Award from the University of California, Berkeley. Dr. Ornish was recognized as a “TIME 100 Innovator;” by Life magazine as “one of the 50 most influential members of his generation”.
“From Human Tumor Biobanking to Human Tumor 3D-Bioprinting: Innovating for Personalized Medicine in Oncology”
Nicolas Forraz, PhD, CTIBiotech, France
Nico Forraz completed his PhD in 2003 at Kingston University and St George’s Hospital Medical School, University of London, UK on multi-tissue differentiation potential of umbilical cord blood stem cell populations with applications to haematology, oncology, tissue engineering and regenerative medicine. After a career in oncology and regenerative medicine in academia he co-founded CTIBiotech, a biotechnology company producing predictive models of human tissues and cells for biomedical, pharmaceutical and dermatocosmetic applications.